India Specialty Chemicals Q2 FY27: Navin Fluorine Up 57%, Acutaas Raises CDMO Target

The Quick Take

• Navin Fluorine delivered 57% revenue growth in Q2 FY27 with 34.2% EBITDA margins, extending its Solstice HFO contract to 2032.
• Acutaas Chemicals raised FY27 revenue growth guidance to ~30% and pulled its INR 1,000 crore CDMO target forward by one full year.
• Shilchar Technologies reaffirmed its INR 750 crore FY27 revenue target backed by an order book exceeding INR 550 crore.
• Dhanuka Agritech guided to low single-digit full-year growth, contrasting with CDMO sector strength.

India specialty chemicals Q2 FY27 delivered a broadly strong season, with CDMO-focused and fluorochemical players showing the most momentum. Navin Fluorine delivered 57% revenue growth alongside high margins and a contract extension cementing its position in the fluoropolymers supply chain serving global pharma and refrigerant end-markets. Acutaas Chemicals pulling its CDMO milestone forward by a year signals that order pipeline visibility has materially improved, consistent with global pharma companies accelerating China-plus-one sourcing diversification into India. Shilchar Technologies in the transformer and power equipment segment is benefiting from the infrastructure capex supercycle.

The earnings divergence between CDMO and fluorochem plays versus agritech is instructive for sector allocation. Dhanuka guidance for low single-digit full-year growth reflects commodity price pressure and input cost inflation in the agrochemical chain, contrasting with the margin expansion at Navin Fluorine and Acutaas. Investors allocating within India chemicals are reinforced to overweight CDMO and specialty fluorochems over pure agritech plays. Capital flows from global funds seeking China-plus-one chemical supply chain exposure continue to benefit the CDMO segment disproportionately among India mid-cap industrials.

The macro variable determining whether this thesis extends into H2 FY27 is the pace of global pharma order finalization. CDMO order books are typically twelve to eighteen months forward; any slowdown in FDA New Molecular Entity approvals could delay order conversions. For Navin Fluorine specifically, watch Honeywell capex guidance — the Solstice HFO contract extension is commercially locked but volume ramp depends on Honeywell downstream market development. Shilchar should be monitored against India power grid expansion timelines, where PGCIL capex announcements will drive order visibility beyond FY27.

Synthesized from 4 sources.